

GE Healthcare and acib will seek to reduce the need for clone screening, recognize suitable tools for cell line engineering, and gain more knowledge about what cellular mechanisms determine cell line efficiency. In the first phase, the collaboration focuses on performing basic research in this area, but in the long-term the work could lead to creation of a pre-engineered host cell line library, where biopharma producers could choose the most suitable cell line to use in the production of any

specific bio pharmaceutical to ensure higher productivity with increased speed and final product quality.

"While the biopharma industry is growing quickly, lack of access to biologic drugs is commonplace in many countries partly due to the complex and time-consuming production methods. Cell line engineering could help us bring major productivity improvements for our customers, making it more feasible to bring biologic manufacturing to more regions. Acib has already conducted some remarkable research in this field, and we believe that this collaboration will increase our understanding of cellular behavior, eventually creating more predictable and reliable manufacturing processes for our customers, biopharma producers", said Morgan Norris, General Manager, Upstream and Cell Culture, GE Healthcare Life Sciences.